RenovoRx Announces Acceptance of Clinical Data Abstract at the ASCO Gastrointestinal Cancers Symposium 2026
Rhea-AI Summary
RenovoRx (Nasdaq: RNXT) announced acceptance of a clinical data abstract at the ASCO Gastrointestinal Cancers Symposium 2026 for a pharmacokinetic/pharmacodynamic sub-study of the Phase III TIGeR-PaC trial.
The sub-study, led by Dr. Paula Novelli, compares intra-arterial gemcitabine delivered via RenovoCath (IAG) to standard intravenous gemcitabine in locally advanced pancreatic cancer and reports decreased systemic drug levels consistent with a reduced clinical side-effect profile for the localized TAMP therapy approach.
The poster (Abstract 732, Poster Board K2) will be presented on January 9, 2026 at Moscone West, San Francisco, during Poster Session B.
Positive
- Phase III TIGeR-PaC PK/PD sub-study accepted at ASCO GI, Jan 9 2026
- Abstract reports decreased systemic gemcitabine levels versus intravenous therapy
- Findings support TAMP localized delivery using RenovoCath (IAG)
Negative
- None.
Key Figures
Market Reality Check
Peers on Argus
RNXT gained 1.76% with mixed peer moves: PSTV up 0.33%, TELO up 0.71%, RENB up 19.33%, while BCAB and TPST fell 0.49% and 2.17%, indicating stock‑specific rather than broad sector momentum.
Historical Context
| Date | Event | Sentiment | Move | Catalyst |
|---|---|---|---|---|
| Dec 01 | Conference presentation | Positive | -6.6% | CEO presentation on RenovoCath commercialization and clinical program updates. |
| Nov 19 | Conference presentation | Positive | -6.4% | CEO conference talk on revenue, TIGeR-PaC progress, and registry data. |
| Nov 13 | Earnings update | Neutral | -2.6% | Q3 2025 results with early RenovoCath revenue and cash of <b>$10.0M</b>. |
| Nov 06 | Management update | Positive | -6.2% | Added pancreatic cancer expert Timothy Donahue to Scientific Advisory Board. |
| Nov 04 | Conference participation | Positive | -6.4% | CEO to discuss RenovoCath commercialization and TIGeR-PaC trial at forum. |
Recent company updates, including conferences, management, and earnings, were generally constructive but were followed by consistent negative 24-hour price reactions.
Over the last months, RenovoRx has focused on RenovoCath commercialization and progression of its pivotal Phase III TIGeR‑PaC trial. Updates included conference presentations on commercial traction and clinical data, a Q3 2025 report with $266,000 revenue and $10.0M cash, and strengthening of its Scientific Advisory Board. Despite these generally positive operational and clinical signals, the stock saw negative 24‑hour reactions after each event, highlighting a pattern of weakness on news.
Regulatory & Risk Context
An effective Form S-3 shelf filed on Nov 14, 2025 allows RNXT to offer up to $50,000,000 in mixed securities over time, supporting TIGeR‑PaC and RenovoCath commercialization but also creating potential for future equity issuance and dilution.
Market Pulse Summary
This announcement highlights acceptance of TIGeR‑PaC pharmacokinetic and pharmacodynamic data for presentation at ASCO GI 2026, adding clinical detail around intra‑arterial gemcitabine delivered via RenovoCath. It builds on prior Phase III updates and pre‑clinical TAMP work. Investors may track how these data complement earlier interim reviews, the company’s reliance on a $50,000,000 shelf and ATM facility, and execution on RenovoCath commercialization as disclosed in recent filings.
Key Terms
pharmacokinetic medical
pharmacodynamic medical
phase iii medical
intra-arterial medical
trans-arterial micro-perfusion medical
AI-generated analysis. Not financial advice.
The Accepted Abstract Provides Supportive Evidence for the TAMP™ Therapy Platform’s Novel, Localized Approach to Targeted Chemotherapeutic Delivery via Additional Pharmacokinetic and Pharmacodynamic Data
MOUNTAIN VIEW, Calif., Dec. 11, 2025 (GLOBE NEWSWIRE) -- RenovoRx, Inc. (“RenovoRx” or “the Company”) (Nasdaq: RNXT), a life-sciences company developing innovative targeted oncology therapies and commercializing RenovoCath®, a patented, FDA-cleared drug-delivery device, is pleased to announce that its abstract submission to the American Society of Clinical Oncology (ASCO) Gastrointestinal Cancers Symposium 2026 (“ASCO GI”) has been accepted.
RenovoRx will present its findings from a pharmacokinetic and pharmacodynamic sub-study of the Company’s ongoing Phase III TIGeR-PaC clinical trial, led by Dr. Paula Novelli of the University of Pittsburgh Medical Center. The sub-study, titled “Intra-arterial Gemcitabine Versus Intravenous Gemcitabine: Pharmacokinetic and Pharmacodynamic Sub-study of the TIGeR-PaC Phase 3 Clinical Trial,” compares systemic drug levels of intra-arterial gemcitabine delivered by the RenovoCath device (IAG) to the standard of care (intravenous chemotherapy) during treatment of locally advanced pancreatic cancer (LAPC).
“This clinical data abstract further contributes to scientific basis for reported decreased clinical side effect profile with our approach to targeted drug-delivery via the TAMP™ (Trans-Arterial Micro-Perfusion) therapy platform and IAG versus the standard of care, systemic intravenous therapy, which is demonstrated by decreased systemic drug levels compared to treatment delivered by systemic therapy,” said Dr. Ramtin Agah, RenovoRx’s Chief Medical Officer and one of the study’s authors.
ASCO GI will be held from January 8-10, 2026, in San Francisco, CA, with the abstract presentation scheduled for January 9, 2026, at 11:30 AM-1:00 PM PT and 5:00-6:00 PM PT. Further details are provided below.
Abstract Details:
Presentation Date & Time: January 9, 2026, at 11:30 AM-1:00 PM PT and 5:00 PM-6:00 PM PT
Location: Moscone West Building – San Francisco, CA
Abstract Number: 732
Poster Board Number: K2
Session Title: Poster Session B: Cancers of the Pancreas, Small Bowel, and Hepatobiliary Tract
Presenter: Dr. Paula M. Novelli, University of Pittsburgh Medical Center
About RenovoCath
Based on its FDA clearance, RenovoCath® is intended for the isolation of blood flow and delivery of fluids, including diagnostic and/or therapeutic agents, to selected sites in the peripheral vascular system. RenovoCath is also indicated for temporary vessel occlusion in applications including arteriography, preoperative occlusion, and chemotherapeutic drug infusion. For further information regarding our RenovoCath Instructions for Use (“IFU”), please see: IFU-10004-Rev.-G-Universal-IFU.pdf.
About the TIGeR-PaC Clinical Trial
TIGeR-PaC is an ongoing Phase III randomized multi-center trial evaluating the proprietary TAMP™ (Trans-Arterial Micro-Perfusion) therapy platform for the treatment of locally advanced pancreatic cancer (LAPC). RenovoRx’s first investigational drug-device combination product candidate, using the TAMP therapy platform enabled with the Company’s FDA-cleared RenovoCath® device, is designed for the intra-arterial administration of chemotherapy, gemcitabine (IAG).
About RenovoRx, Inc.
RenovoRx, Inc. (Nasdaq: RNXT) is a life sciences company developing innovative targeted oncology therapies and commercializing RenovoCath®, a novel, U.S. Food and Drug Administration (FDA)-cleared local drug-delivery device, targeting high unmet medical needs. RenovoRx’s patented Trans-Arterial Micro-Perfusion (TAMP™) therapy platform is designed for targeted therapeutic delivery across the arterial wall near the tumor site to bathe the target tumor, while potentially minimizing a therapy’s toxicities versus systemic intravenous therapy. RenovoRx’s novel approach to targeted treatment offers the potential for increased safety, tolerance, and improved efficacy, and its mission is to transform the lives of cancer patients by providing innovative solutions to enable targeted delivery of diagnostic and therapeutic agents.
RenovoRx is in the early stages of actively commercializing its TAMP technology and FDA-cleared RenovoCath as a stand-alone device. In December 2024, RenovoRx announced the receipt of its first commercial purchase orders for RenovoCath devices, and for the first nine months of 2025, approximately
RenovoRx is also evaluating its novel drug-device combination oncology product candidate (intra-arterial gemcitabine delivered via RenovoCath, known as IAG) in the ongoing Phase III TIGeR-PaC trial. IAG is being evaluated by the Center for Drug Evaluation and Research (the drug division of the FDA) under a U.S. investigational new drug application that is regulated by the FDA’s 21 CFR 312 pathway. IAG utilizes RenovoCath, the Company’s patented, FDA-cleared drug-delivery device, indicated for temporary vessel occlusion in applications including arteriography, preoperative occlusion, and chemotherapeutic drug infusion.
The combination product candidate (IAG), which is enabled by the RenovoCath device, is currently under investigation and has not been approved for commercial sale. RenovoCath with gemcitabine received Orphan Drug Designation for pancreatic cancer and bile duct cancer, which provides seven years of market exclusivity upon new drug application approval by the FDA.
For more information, visit www.renovorx.com. Follow RenovoRx on Facebook, LinkedIn, and X.
Cautionary Note Regarding Forward-Looking Statements
This press release and statements of the Company’s management made in connection therewith described herein contain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, and Section 21E of the Securities Exchange Act of 1934, including but not limited to statements regarding (i) our clinical trials and studies, including the anticipated benefits to the Company of the clinical study abstract described herein, (ii) the potential for our product candidates to treat or provide clinically meaningful outcomes for certain medical conditions or diseases and (iii) our efforts to commercialize RenovoCath and our TAMP technology. Statements that are not purely historical are forward-looking statements. The forward-looking statements contained herein are based upon our current expectations and beliefs regarding future events, many of which, by their nature, are inherently uncertain, outside of our control and involve assumptions that may never materialize or may prove to be incorrect. These may include estimates, projections and statements relating to our research and development plans, intellectual property development, clinical trials, our therapy platform, business plans, financing plans, objectives and expected operating results, which are based on current expectations and assumptions that are subject to known and unknown risks and uncertainties that may cause actual results to differ materially and adversely from those expressed or implied by these forward-looking statements. These statements may be identified using words such as “may,” “expects,” “plans,” “aims,” “anticipates,” “believes,” “forecasts,” “estimates,” “intends,” and “potential,” or the negative of these terms or other comparable terminology regarding RenovoRx’s expectations strategy, plans or intentions, although not all forward-looking statements contain these words. These forward-looking statements are subject to a number of risks, uncertainties and assumptions, that could cause actual events to differ materially from those projected or indicated by such statements, including, among other things: (i) the risk that our commercial sales efforts for RenovoCath and our TAMP technology may not lead to viable, revenue generating operations; (ii) circumstances which would adversely impact our ability to efficiently utilize our cash resources on hand or raise additional funding; (iii) the timing of the initiation, progress and potential results (including the results of interim analyses) of our preclinical studies, clinical trials and our research programs; (iv) the possibility that interim results may not be predictive of the outcome of our clinical trials, which may not demonstrate sufficient safety and efficacy to support regulatory approval of our product candidate; (v) that the applicable regulatory authorities may disagree with our interpretation of the data; research and clinical development plans and timelines, and the regulatory process for our product candidates; (vi) future potential regulatory milestones for our product candidates, including those related to current and planned clinical studies; (vii) our ability to use and expand our therapy platform to build a pipeline of product candidates; (viii) our ability to advance product candidates into, and successfully complete, clinical trials; (ix) the timing or likelihood of regulatory filings and approvals; (x) our estimates of the number of patients who suffer from the diseases we are targeting and the number of patients that may enroll in our clinical trials; (xi) the commercialization potential of our product candidates, if approved; (xii) our ability and the potential to successfully manufacture and supply our product candidates for clinical trials and for commercial use, if approved; (xiii) future strategic arrangements and/or collaborations and the potential benefits of such arrangements; (xiv) our estimates regarding expenses, future revenue, capital requirements and needs for additional financing and our ability to obtain additional capital; (xv) the sufficiency of our existing cash and cash equivalents to fund our future operating expenses and capital expenditure requirements; (xvi) our ability to retain the continued service of our key personnel and to identify, and hire and retain additional qualified personnel; (xvii) the implementation of our strategic plans for our business and product candidates; (xviii) the scope of protection we are able to establish and maintain for intellectual property rights, including our therapy platform, product candidates and research programs; (xix) our ability to contract with third-party suppliers and manufacturers and their ability to perform adequately; (xx) the pricing, coverage and reimbursement of our product candidates, if approved; and (xxi) developments relating to our competitors and our industry, including competing product candidates and therapies. Information regarding the foregoing and additional risks may be found in the section entitled “Risk Factors” in documents that we file from time to time with the Securities and Exchange Commission.
Forward-looking statements included herein are made as of the date hereof, and RenovoRx does not undertake any obligation to update publicly such forward-looking statements to reflect subsequent events or circumstances, except as required by law.
Contact:
KCSA Strategic Communications
Valter Pinto or Jack Perkins
T:212-896-1254
RenovoRx@KCSA.com
FAQ
When will RenovoRx (RNXT) present the TIGeR-PaC PK/PD sub-study at ASCO GI 2026?
What did the RNXT abstract compare in the TIGeR-PaC sub-study?
What key result does the RNXT abstract report about systemic drug exposure?
Who is presenting RenovoRx's abstract for TIGeR-PaC at ASCO GI 2026?
What is the clinical significance of the RNXT ASCO GI abstract for investors?
